Trade Names:Hyperstat IV- Injection 15 mg/mL
Relaxes smooth muscle in peripheral arterioles, thus reducing BP.
Greater than 90% protein bound. Crosses placenta.
t ½ approximately 28 h.
2 to 5 min.
Less than 12 h.
Short-term emergency reduction of BP in severe, nonmalignant, and malignant hypertension in hospitalized patients.
Dissecting aortic aneurysm; hypersensitivity to thiazides or other sulfonamide derivatives; treatment of compensatory hypertension, such as that associated with aortic coarctation or arteriovenous shunt. Diazoxide is ineffective against hypertension caused by pheochromocytoma.
IV 1 to 3 mg/kg (max 150 mg in single injection) by rapid injection (no longer than 30 sec). May repeat at 5 to 15 min intervals until satisfactory reduction in BP. May repeat at intervals of 4 to 24 h until oral therapy can be initiated. Do not use for longer than 10 days. Have patient remain supine during IV administration.
Protect from light/freezing. Store between 2° to 30°C (36° to 86°F).
Enhanced antihypertensive effect.Highly protein-bound agents
Higher blood levels of these agents may occur as a result of displacement by diazoxide.Hydantoins
Possible loss of seizure control.Sulfonylureas
Hyperglycemia may occur.Thiazide diuretics
May increase hyperuricemic, hyperglycemic, and antihypertensive effects of diazoxide.
Hyperglycemia and hyperuricemia produced by diazoxide may affect assessment of these metabolic states. Increased renin secretion and IgG concentrations and decreased cortisol secretion may occur. May cause false-negative insulin response to glucagon.
Sodium and water retention; hypotension to shock levels; CHF; edema; myocardial ischemia (eg, angina, arrhythmias, ECG changes); supraventricular tachycardia; palpitations; bradycardia.
Dizziness; weakness; cerebral ischemia; cerebral infarction (eg, unconsciousness, convulsions, paralysis, confusion, focal neurologic deficit); sweating; flushing and feelings of warmth; transient neurologic findings (eg, headache, lethargy, somnolence, euphoria, ringing in the ears, momentary hearing loss).
Cellulitis or phlebitis at site of extravasation; warmth or pain along course of injected vein.
Nausea; vomiting; acute pancreatitis (rare); diarrhea; abdominal discomfort.
Hyperglycemia; hyperosmolar coma; hyperuricemia.
Hypersensitivity reactions; papilledema.
Category C .
Diabetic patients may need treatment for hyperglycemia. Use with care in patients with impaired cerebral or cardiac circulation in whom rapid reduction in BP might be deleterious. Observe caution when reducing severely elevated BP.
Because of sodium and water retention, with possible edema and CHF, concomitant use of diuretic may be needed. However, thiazide diuretics may potentiate diazoxide's antihypertensive, hyperglycemic, and hyperuricemic actions.